Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
June 1, 2010
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies
Rebecca L Elstrom, Peter Martin, Katya Ostrow, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 7, 2025
Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference
Alexey V Danilov, Craig Sauter, Tycel Phillips, et al.
Blood Advances
|
March 10, 2020
CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation
Boris A Bartholdy, Xiahoua Wang, Xiao-Jie Yan, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 3, 2015
TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells
Patricia K A Mongini, Rashmi Gupta, Erin Boyle, et al.
JCI Insight
|
May 10, 2016
Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process
Piers E M Patten, Gerardo Ferrer, Shih-Shih Chen, et al.
Blood Advances
|
November 19, 2024
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL
Jacob D Soumerai, Jacqueline Barrientos, Inhye Ahn, et al.
Blood
|
October 17, 2012
IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions
Piers E M Patten, Charles C Chu, Emilia Albesiano, et al.
The New England Journal of Medicine
|
August 1, 2019
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Tait D Shanafelt, Xin V Wang, Neil E Kay, et al.
Blood
|
December 27, 2019
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
John C Byrd, William G Wierda, Anna Schuh, et al.
Blood
|
April 15, 2022
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Clinical Lymphoma, Myeloma & Leukemia
|
June 1, 2010
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies
Rebecca L Elstrom, Peter Martin, Katya Ostrow, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 7, 2025
Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference
Alexey V Danilov, Craig Sauter, Tycel Phillips, et al.
Blood Advances
|
March 10, 2020
CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation
Boris A Bartholdy, Xiahoua Wang, Xiao-Jie Yan, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 3, 2015
TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells
Patricia K A Mongini, Rashmi Gupta, Erin Boyle, et al.
JCI Insight
|
May 10, 2016
Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process
Piers E M Patten, Gerardo Ferrer, Shih-Shih Chen, et al.
Blood Advances
|
November 19, 2024
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL
Jacob D Soumerai, Jacqueline Barrientos, Inhye Ahn, et al.
Blood
|
October 17, 2012
IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions
Piers E M Patten, Charles C Chu, Emilia Albesiano, et al.
The New England Journal of Medicine
|
August 1, 2019
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Tait D Shanafelt, Xin V Wang, Neil E Kay, et al.
Blood
|
December 27, 2019
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
John C Byrd, William G Wierda, Anna Schuh, et al.
Blood
|
April 15, 2022
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, et al.
Page
of 3